Home » CONDITIONAL OK GIVEN FOR CEPHALON'S SPARLON
CONDITIONAL OK GIVEN FOR CEPHALON'S SPARLON
Cephalon has received conditional FDA approval from regulators for Sparlon,
a treatment for attention-deficit/hyperactivity disorder (ADHD) that has the
same active ingredient as the company's Provigil.
Sparlon, which had been previously known as Attenace, is designed for ADHD in
children and adolescents aged 6 through 17. Cephalon expects to launch Sparlon
in early 2006, depending upon final FDA approval.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May